SCHEMBL26259484

SCHEMBL26259484

COc1ccc2c(-c3ccccc3)c(OC)cc(-c3ccccc3)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ HPGD P15428 4/20 0.51
▸ KMT2A Q03164 4/20 0.50
▸ PIN1 Q13526 1/20 0.50
▸ MEN1 O00255 3/20 0.49
▸ CYP3A4 P08684 3/20 0.46
▸ CYP1A2 P05177 3/20 0.46
▸ CYP2C9 P11712 3/20 0.46
▸ CYP2C19 P33261 3/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ CYP1A1 P04798 1/20 0.46
▸ CYP2E1 P05181 1/20 0.46
▸ CYP2C8 P10632 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ CYP4B1 P13584 1/20 0.46
▸ CYP2B6 P20813 1/20 0.46
▸ CYP3A5 P20815 1/20 0.46
▸ CYP2A7 P20853 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13511558 0.87 ACACA (0.50) SMN1; SMN2HPGDKMT2AMEN1MAPT
SCHEMBL26259504 0.85 MAPK13 (0.46) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL14981133 0.84 ACACA (0.46) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL26260061 0.80 KDM4E (0.57) KDM4EALDH1A1HPGDCYP3A4CYP1A2
SCHEMBL29416178 0.80 KCNA5 (0.52) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL1758790 0.80 KCNA5 (0.52) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL14076794 0.78 KCNA5 (0.51) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL26260045 0.78 MAOB (0.46) CYP3A4CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL26260037 0.78 CYP11B1 (0.53) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL12126776 0.78 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND NUDC, CCNL2, SPIN3 KDM4E 1663/4885ALDH1A1 2125/4885SMN1; SMN2 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback